|Videos|May 20, 2021

The Ever-Expanding Multiple Sclerosis Therapeutics

Author(s)Ahmed Obeidat, MD, PhD, Mitchell Freedman, MD, Suma Shah, MD

Join Ahmed Obeidat, MD, PhD; Mitchell Freedman, MD; and Suma Shah, MD, for the second program of this monthly series as they discuss the evolution of therapeutics for the treatment of multiple sclerosis.

————————————

Panelists

Ahmed Obeidat, MD, PhD
Assistant Professor, Department of Neurology, Neuroimmunology and Multiple Sclerosis; Director, Neuroimmunology and MS Fellowship Program, The Medical College of Wisconsin
Suma Shah, MD
Director, MS & Neuroimmunology Fellowship, Duke University School of Medicine
S. Mitchell Freedman, MD FAAN
Adjunct Professor of Neurology, University of North Carolina-Chapel Hill

Key Learning Objectives

Virtual patient visits during COVID-19 when treating MS
Changing barriers to treating MS
Evolution of monitoring safety and efficacy of therapy
The future of treating MS

Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.

Latest CME

Video

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

Jeffrey Gudin, MD; Jeffrey Bettinger, PharmD

In-Person + Virtual Event

2026 Carolina Neuromuscular Disease Summit

September 19-20, 2026

In-Person Event

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

October 16, 2026

In-Person + Virtual Event

Primary Care Education in Nashville

October 20-21, 2026

Multimedia

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Zarazuela Zolkipli-Cunningham, MBChB, MRCP; Mary Kay Koenig, MD; Perry Shieh, MD, PhD, FAAN, FANA

Video

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Anne M. Connolly, MD, FAAN; Amy Moore, PhD

Video

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Karissa Gable, MD

Video

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Jessica Oswald, MD, MPH; Jeremy A. Adler, DMSc, PA-C; Amanda Nasser, MS, NP

Video

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA, FASCO; Girish Dhall, MD

Video

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Millie Das, MD; Wade Iams, MD, MSCI; Ruham Nasany, MD

Video

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Multimedia

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

James F. Howard Jr, MD, FAAN; Tuan Vu, MD

Video

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Charu Aggarwal, MD, MPH, FASCO; Erminia Massarelli, MD, PhD, MS; Ruham Nasany, MD

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts Ecopipam NDA for Tourette Syndrome, Remlifanserin Receives Fast Track Designation for AD Psychosis, Alterity Reaches FDA Alignment on ATH434

The Ever-Expanding Multiple Sclerosis Therapeutics

Related Content

AMO Pharma Aligns With Regulators on Registrational Study for AMO-02 in Myotonic Dystrophy

FDA Accepts Ecopipam NDA for Tourette Syndrome, Remlifanserin Receives Fast Track Designation for AD Psychosis, Alterity Reaches FDA Alignment on ATH434

NeurologyLive® Friday 5 — August 21, 2026

FDA Clears PrecivityAD2 Alzheimer Blood Test for Symptomatic Patients 40 and Older

Where Adults With SMA May Fall Out of the Care System

Latest CME

Patient, Provider, and Caregiver Connection: Turning a New Leaf in Acute Pain Management – How Recent Advancements Impact the Treatment Paradigm

2026 Carolina Neuromuscular Disease Summit

Increasing Awareness of Therapeutic Options for Thymidine Kinase 2 Deficiency (TK2d)

Primary Care Education in Nashville

Shining a Light on an Ultra-Rare Disease – A Closer Look at Thymidine Kinase 2 Deficiency (TK2d)

Expert Illustrations & Commentaries™: Visualizing the Role of Dystrophin Dysregulation as a Therapeutic Target in Duchenne Muscular Dystrophy and MD STARnet

Rewiring Recovery: Evidence-Based Approaches to Managing Chronic Inflammatory Demyelinating Polyneuropathy

Putting the Patient First in Acute Pain Management: The PA’s Guide to Incorporating Cutting-Edge Science Into Their Treatment Strategies

Unlocking the Future of Glioma Care: Integrating Recent Advances to Personalize Treatment

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Community Collab™: Identifying the Role of Complement Inhibitors in the Management of Generalized Myasthenia Gravis

Community Collab: The Evolving Role of FcRN Inhibitors in the Management of Generalized Myasthenia Gravis (gMG)

From Suspicion to Stabilization: Early Recognition and Treatment of Paraneoplastic LEMS

Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights

FDA Accepts Ecopipam NDA for Tourette Syndrome, Remlifanserin Receives Fast Track Designation for AD Psychosis, Alterity Reaches FDA Alignment on ATH434

FDA Clears PrecivityAD2 Alzheimer Blood Test for Symptomatic Patients 40 and Older

TEMPO-2 Data Supports Tavapadon’s Efficacy in Early-Stage Parkinson Disease

FDA Grants Fast Track Designation to Remlifanserin for Alzheimer Disease Psychosis

Episode 173: Exploring the Emerging Role of GLP-1 Therapies in Neurology